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procedures in the studies reviewed made it difficult to compare disease 
epidemiology across studies/countries, and understand disease trends overtime. 
Data suggested that the majority of hypogonadal individuals in the general 
population currently receive no treatment for the condition. Future studies 
should use consistent, internationally-accepted diagnostic criteria to define 
hypogonadism.  
 
PIH8  
PREVALENCE OF ANTI-DIABETIC AND ANTILIPIDEMIC MEDICATIONS IN 
CHILDREN AND ADOLESCENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS 
IN A VIRGINIA MEDICAID POPULATION  
Varghese D1, Kirkwood CK1, Carroll NV1, Kennedy MJ1, Proffitt DF2 
1Virginia Commonwealth University, Richmond, VA, USA, 2Department of Medical Assistance 
Services, richmond, VA, USA  
OBJECTIVES: To determine and compare the prevalence of use of anti-diabetic 
and antilipidemic medications in children and adolescents treated with atypical 
antipsychotics to those not treated with atypical antipsychotics. METHODS: 
Virginia Medicaid beneficiaries (between 2 and 17 years) continuously enrolled 
from August 1, 2010 to July 31, 2011 were included in the study. Subjects with at 
least two paid prescription claims for aripiprazole, olanzapine, quetiapine, 
risperidone, or ziprasidone were assigned to the exposed group. All other 
subjects in the Virginia Medicaid system during the study period were assigned 
to the non-exposed group. Prevalence of anti-diabetic and antilipidemic 
medication use in both groups were computed and compared using Chi-square 
test (α=0.05). Generic Code Numbers were used to identify all medications. 
RESULTS: A total of 299,593 patients (2,286,629 claims) were identified as  
the non-exposed group (mean age: 8.23 +/- 4.70 years, 50.10% males). Of these 
patients, 0.32% had prescription claims for anti-diabetic medications (mean  
age: 13.82 +/- 2.67 years, 28.42% males), and 0.087% had prescription claims  
for antilipidemic medications (mean age: 11.82 +/- 4.93 years, 55.94% males).  
A total of 5,663 patients had 53,236 claims for atypical antipsychotic agents 
(mean age: 12.02 +/- 3.63 years, 63.13% males). In this group 1.66% had 
prescription claims for anti-diabetic medications, and 0.37% had prescription 
claims for antilipidemic medications. There was a significantly higher rate of 
anti-diabetic and antilipidemic drug use in the exposed group compared with the 
non-exposed group (p<0.0001). Among the atypical anti-psychotic users, the 
highest number of claims was for risperidone (50.98%). The prevalence of 
antidiabetic medication claims was highest for ziprasidone (7.53%) and the 
prevalence of antilipidemic medications was highest for olanzapine (1.45%). 
CONCLUSIONS: The prevalence of anti-diabetic and antilipidemic medication 
use was higher among children and adolescents in the Virginia Medicaid 
population prescribed atypical antipsychotics than those not prescribed atypical 
antipsychotics.  
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THE BURDEN OF DISEASE OF WOMEN IN MID-EAST, QATAR  
Kim EJ1, Yoon SJ2, Bener A3 
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OBJECTIVES: Qatar is one of the highest GDP in the world so the health care 
facility has high quality. But the men powers or technical skills have been 
underdeveloped compared to the similar GDP status countries. In addition, due 
to the peculiarity of culture and religion, the social activities of women are 
prohibited. These characters can effect on the burden of disease of Qatar. So in 
this study, We calculate the burden of disease then increase the international 
comparability. METHODS: Qatar has had no social insurance or medical 
insurance so our research team could get the mortality data and the inpatients 
data from the national hospitals in Qatar and the national community health 
research. Using the data, we calculated DALYs of Qatar. But in the case of visiting 
the primary health care center or outpatients, they didn’t use ICD code for the 
recording disease diagnosis. So there was some limitations regarding medical 
record data application. Qatar used ICD-9 code for their disease diagnosis then 
we converted to ICD-10 code then calculated DALYs. We used Dismod-II for 
estimating the age of onset and the illness of duration. For the disease disability, 
we applied disability weight of WHO. RESULTS: The most burden diseases in 
Qatar were perinatal diseases. Major 5 diseases among top 15 diseases were 
perinatal related diseases. Especially, asphyxia and birth trauma which were 
appeared during labor were the highest burden of diseases of 
women(9.02DALY/100,000 persons). CONCLUSIONS: The burden of diseases of 
Qatar was likely to developing country even though their high GDP. That is, the 
burden of perinatal diseases was higher but the burden of chronic diseases was 
lower. Especially, compare to other developed countries, the burden of abortion 
was high. It meant that the cultural specialties like a favoritism of boy was 
reflected. These kinds of diseases(like perinatal diseases) could decrease training 
people as obstetric professions.  
 
PIH10  
FACTORS ASSOCIATED WITH INITIATION OF TESTOSTERONE REPLACEMENT 
THERAPY IN AGING MALES  
An J, Niu F, Cheetham CT 
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OBJECTIVES: Testosterone replacement therapy is a widespread and growing 
practice for treating androgen deficiency. Many patients with androgen 
deficiency however remain untreated. The purpose of this study is to investigate 
the factors associated with testosterone therapy in aging males. METHODS: We 
identified patients with androgen deficiency based on ICD-9-CM diagnosis codes 
between January 1999 and December 2010 in Kaiser Permanente Southern 
California. The first diagnosis date was labeled as the index date. We excluded 
patients with: 1) age <45, 2) genetic indications for testosterone, 3) hypothalamic 
or pituitary dysfunction, 4) testicular, pituitary or prostate cancer, and 5) a 
testosterone prescription in the prior 12 months. Twelve months continuous 
membership before the index date was required for inclusion in the cohort. 
Multivariate logistic regression was used to identify factors (demographics, 
baseline testosterone levels and prostate-specific antigen levels [PSA], baseline 
comorbidity, and medication usage, physician characteristics and other health 
care system factors) associated with testosterone initiation. RESULTS: Among 
the identified patients (N=8,261), 33% (N=2,706) initiated testosterone within one 
year following the index date. Patient level factors significantly associated with 
testosterone treatment included younger age (odds ratio (OR)=1.37, 95% CI: 1.19-
1.57 for age 45-54 vs. 65-74), white race (OR=1.34 ,1.12-1.60 for white vs. black), 
low baseline testosterone level (OR=1.86, 1.61-2.15 for testosterone <200 vs. >300 
ng/dL), and low baseline PSA level (OR=1.38, 1.08-1.77 for PSA <4 vs. ≥4 ng/dL). 
Health care system factors significantly associated with treatment initiation: 
younger physician age (OR=1.26, 1.10-1.44 for age ≤40 vs. 51-60), male physician 
gender (OR=1.19, 1.05-1.36 for male vs. female), urology physician specialty 
(OR=1.41, 1.12-1.78 for urology vs. family medicine), health care facility location 
and year of the diagnosis. CONCLUSIONS: Patient and health care system factors 
were significantly associated with initiation of testosterone treatment. Future 
studies should evaluate age and racial differences in addition to health system 
factors.  
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THE USAGE OF 2-OCTYL CYANOACRYLATE POST CESAREAN-SECTION IN 
CANADIAN HOSPITALS: A BUDGET IMPACT ANALYSIS  
Goldstein LJ 
Johnson & Johnson Medical Companies, Markham, ON, Canada  
OBJECTIVES: In Canada, approximately 25% of all births are delivered via 
cesarean section and this rate continues to rise. C-sections are associated with 
up to 20 times the surgical site infection (SSI) incidence rate as compared to 
vaginal births. A recent Canadian prospective trial assessing SSI in women after 
c-section found the incidence rate to be 7%. This study was conducted to 
determine the budget impact of incorporating the use of 2-Octyl cyanoacrylate in 
Canadian hospitals as an anti-microbial topical skin adhesive after c-section. 
METHODS: Clinical and economic data was obtained from peer-reviewed 
literature and through case-costing data from a large Canadian hospital. The 
efficacy data used to demonstrate a reduction in SSIs from the use of 2-Octyl 
cyanoacrylate was obtained through a large retrospective trial. One and two way 
sensitivity analyses were conducted on economic and clinical parameters to 
ensure robustness. RESULTS: Incorporating 2-Octyl cyanoacrylate use as an anti-
microbial tissue sealant after c-section has been found to reduce the incidence of 
SSI from 7.0% to 3.01%. Based on model calculations a hospital that completes a 
total of 500 c-sections per year would see 35 of its patients develop a SSI using 
standard preventative strategies. By incorporating the use of 2-Octyl 
cyanoacrylate into the standard of care the same hospital would see 
approximately 15 SSIs in the same patient population, for a total reduction of 20 
SSIs. Treatment costs for SSI vary greatly dependent on whether the infection is 
superficial or deep/organ space. Taking this into account, the model establishes 
that the use of 2-Octyl cyanoacrylate has the potential to provide a yearly net 
cost savings of $232, 660.00 when compared to the use of standard wound 
closure products. CONCLUSIONS: 2-Octyl cyanoacrylate is an anti-microbial 
tissue sealant that can be used cost-effectively post c-section in Canadian 
hospitals.  
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INTRODUCTION OF A LOW-DOSE LEVONORGESTREL INTRAUTERINE 
CONTRACEPTIVE SYSTEM: A THREE-YEAR BUDGET IMPACT ANALYSIS  
FROM A THIRD-PARTY PAYER PERSPECTIVE IN THE UNITED STATES  
Trussell J1, Ferrufino CP2, Hawes C3, Pocoski J4, Filonenko A5, Kim RS4, McCoy MA4,  
Law AW4 
1Princeton University, Princeton, NJ, USA, 2IMS Health, Alexandria, VA, USA, 3IMS Health, 
London, UK, 4Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ, USA, 5Bayer Pharma AG,  
Berlin, Germany  
OBJECTIVES: Contraceptive methods vary by effectiveness, duration of effect and 
product-related costs. Consideration of both product- and unintended pregnancy 
(UP)-related costs over the full duration of effect is vital when health care payers 
make contraceptive coverage decisions. This analysis aimed to estimate the 
medical and pharmacy budget impact to a US health care plan when switching 
women from short-acting reversible contraceptives (SARC) to a low-dose 
levonorgestrel intrauterine system (LNG-IUS-12). METHODS: A three-year budget 
impact model was developed to estimate costs before and after availability of 
LNG-IUS-12, among women aged 15-44 years, at risk of UP, and covered by a US 
health care plan. US Census and National Survey of Family Growth determined 
current contraceptive usage. Pregnancy outcomes and failure rates were 
estimated using published literature. The model considered costs of 
contraceptives derived from Wolters Kluwers Health-MediSpan Master Drug 
Database, physician visits from Medicare Reimbursement Rate and pregnancy 
outcomes (live birth, induced or spontaneous abortion, and ectopic pregnancy) 
from the Health Care Utilization Project. Consistent with the Health and Human 
Services mandate on preventive services, no patient co-pay, co-insurance, or 
deductible was factored into this analysis. LNG-IUS-12 was assumed to gain 
0.5%, 0.3% and 0.2% market share from SARC methods in years 1, 2 and 3 
respectively, resulting in a target cumulative 1% uptake of the contraceptive 
market by year 3. A potential 20% discontinuation rate for LNG-IUS-12 in the 1st 
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year was considered. Base case model outputs were total cost, cost per member 
per month (PMPM) and number of UP. RESULTS: In a hypothetical cohort of 1 
million plan members, the model estimated reductions of $460,552USD in total 
costs, $0.03USD in PMPM costs, and 119 in UP. CONCLUSIONS: Switching SARC 
method users to LNG-IUS-12 in a US health care plan may result in fewer UP and 
an overall cost savings to the plan.  
 
PIH13  
ECONOMIC CONSIDERATIONS FOR MID-URETHRAL SLING PROCEDURES 
AMONG PATIENTS WITH STRESS URINARY INCONTINENCE  
Roy S1, Bramley T2, Hinoul P3, Li H4 
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OBJECTIVES: Stress urinary incontinence (SUI) is associated with a hefty 
economic burden. Mid-urethral slings have become common surgical options for 
women with SUI. This study examines the costs of transobturator slings for SUI 
surgeries. METHODS: A model was created to estimate the budget impact to 
hospitals of transobturator sling surgery in women with SUI. Current practice 
using transobturator slings including the Monarc™ Subfascial Hammock, 
Obtryx® Transobturator Mid-Urethral Sling System, Aris® Transobturator Sling 
System, Align® TO Trans-Obturator Urethral Support System, Desara® Sling 
System, Gynecare TVT™ Obturator System Tension-free Support for 
Incontinence and Gynecare TVT Abbrevo™ Continence System were modeled. 
Four surgical complications were also considered: re-operation due to failure, 
revision or removal of sling, urologic complications including urinary obstruction 
and urinary tract infection, and pelvic complications. This model calculates the 
average one-year cost per patient with the use of each sling product and predicts 
the total budget for sling urinary incontinence surgery associated with each 
product based on these estimates. RESULTS: Average combined cost of the sling 
and for management of complications over one year ranged from $2,666 
(Gynecare TVT™ Obturator) to $3,213 (Desara®) per patient. With the current 
market share for transobturator sling products, the expected expenditure is 
around $293,669 for a hypothetical surgical population of 100 patients. Sling 
costs account for approximately $105,526 (36%) of this cost with complications 
making up the remainder. While cost of Gynecare slings are not the least, 
increase in the share of use of these slings resulted in lowering of overall 
expenditure. CONCLUSIONS: This study represents the first comparative 
assessment of the costs of different sling options for SUI surgeries. Gynecare 
transobturator slings represent a sound economic choice for hospitals with an 
expected reduction in overall expenditure compared with others. Moreover, such 
reduction is obtained at the benefit of patients who experience fewer 
complications.  
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BUDGET IMPACT ANALYSIS OF THE USE OF TOBRAMYCIN INHALATION 
POWDER (TIP) FOR THE TREATMENT OF CHRONIC PSEUDOMONAS 
AERUGINOSA (PA) INFECTION IN PATIENTS WITH CYSTIC FIBROSIS  
AGED ≥ 6 YEARS IN MEXICO  
Lemus A1, Rosas J2 
1Novartis, Mexico City, Mexico, 2ESEAC Consultores, Mexico City, Mexico  
OBJECTIVES: To estimate the budget impact analysis of replacing Tobramycin 
Inhalation Solution (TIS) by TIP in the public health care system. METHODS: A 
financial cash flow of treatment, concomitant treatment (ciprofloxacin) was 
estimated using TIP instead of TIS in the 315 patients currently identified 
receiving treatment. Efficacy is the same between the two presentations 
(Konstan, 2011); adverse events do not represent additional costs. However the 
time needed to nebulization treatment, and device cleaning is longer with TIS: 28 
and 33 minutes more per day, respectively. Therefore a societal impact is 
estimated using the societal time value for economic evaluations of US$2.64 
hour. (ER 1US$=13MX$). RESULTS: The cycle cost per patient of TIS=US$2269.23 
and TIP=US$2155.76. The annual 6-cycles cost is US$13,617.81 for TIS and 
US$12,937.21 for TIP. Savings account for US$680.52 per patient (5%). The Health 
System could be saving US$214,442.30. The difference in the hours invested to 
drug administration between TIS and TIP is 78.4 hours-year, and the difference 
for cleaning the device is 92.4 hours-year, less for TIP in both cases. 
Economically, it represents an incremental societal investment of using TIS of 
$1798 per patient a year. CONCLUSIONS: The time burden to receive treatment 
in CF is huge. Patients spend around 2 hours a day. TIP represents an 
opportunity for saving both health care resources, and valuable time to patients, 
and caregivers.  
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COST SAVINGS AND COST-EFFECTIVENESS OF THE CONTRACEPTIVE 
MANDATE IN THE PATIENT PROTECTION AND AFFORDABLE CARE  
ACT  
Montouchet C, Hart P 
Medaxial Group, London, UK  
OBJECTIVES: Health economic analyses have shown that providing free 
contraceptive cover leads to cost savings of 15–17% when considering the cost of 
managing unintended pregnancies and their outcomes. The US Patient 
Protection and Affordable Care Act (PPACA) mandates employers to include 
contraceptives in their employees’ health care coverage at no out-of-pocket cost 
to women. This model estimates the budget impact and cost-effectiveness to the 
US health care system of providing this coverage to women across different 
employment and insurance settings. METHODS: An age-specific Markov model 
was developed for women aged 15–44, using data from the US Census Bureau 
and National Survey of Family Growth. The model explored direct medical costs 
associated with contraceptive coverage. The direct medical costs of unintended 
pregnancy (live birth, abortion, miscarriage and ectopic pregnancy) were sourced 
from published literature identified using Pubmed. The model considered the 
impact of altered contraceptive use associated with free coverage (using data 
from the CHOICE study), and accounted for differences in efficacy between these 
modalities. RESULTS: The model showed that savings may be realised by the US 
health care system when contraceptives are provided free of charge to women at 
risk of unintended pregnancy, a strategy which remained cost-effective over a 
variety of sensitivity analyses. Key drivers of savings included the tenfold 
increase in recourse to long-acting reversible contraceptive methods, which led 
to a three- and five-fold decrease in unintended pregnancies and associated 
medical costs, respectively. CONCLUSIONS: This model is the first to estimate 
the impact, to the US health care system, of the PPACA mandate for free 
contraception, accounting for revised contraceptive usage when coverage is 
provided with no out-of-pocket costs. Findings suggest that providing 
contraception free of charge is cost-effective and cost-saving for the US health 
care system, and could be even more so were indirect and intangible costs 
considered.  
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OBJECTIVES: Rotavirus (RV) is the leading cause of severe gastroenteritis in 
infants and young children worldwide. We aimed to assess the cost-
effectiveness of two different RV vaccines in Mexico. METHODS: The analysis 
was conducted by calibrating a previously published deterministic Markov model 
with existing national data. Competing alternatives included routine 
immunization with a two-dose (2d: first/second dose at 2/4 months of age) or a 
three-dose (3d: first/second/third dose at 2/4/6 months of age) schemes besides 
the non-vaccination strategy. The model simulated the vaccines effect at vaccine 
steady-state condition over a period of 5 years under the perspective of Mexican 
public health care system. Direct medical costs comprising both acquisition and 
administration of RV vaccines as well as treatment of emerging RV infections 
were assessed. Costs are expressed in 2012 Mexican pesos (MXN). It was 
assumed that once completed, both vaccines are equally effective. Therefore, 
compliance and efficacy per each dose were incorporated into the analysis. 
Utility scores were obtained from literature. A 5% annual discount rate was 
applied. RESULTS: Without vaccination 760,559 cumulative RV events are 
expected for the 2012 birth cohort, entailing direct medical costs of 529.3 million 
MXN and a loss of 5,036 quality-adjusted life years (QALY). The two-dose scheme 
reduced RV events (39%), frequency of cases seeking medical advice (58%)  
and hospital admissions due to RV (67%). For 3d, these reductions were 30%, 45% 
and 53%, respectively. When compared to non-vaccination, the costs per 
additional QALY gained were $26,408 MXN (2d) and $69,325 MXN (3d). 2d  
was associated with net savings of 74 million MXN (11%) plus a gain of 553 QALY 
with respect to 3d. Sensitivity analysis showed model is robust. CONCLUSIONS: 
These results suggest routine immunization against RV with either 2d or 3d is a 
highly cost-effective intervention in Mexico. Among the vaccines, 2d was 
dominant.  
 
PIH17  
RETROSPECTIVE DATABASE ANALYSIS OF CLINICAL OUTCOMES AND COSTS 
FOR TREATMENT OF MENORRHAGIA AMONG WOMEN ENROLLED IN MEDICAID 
PROGRAMS IN THE UNITED STATES  
Bonafede MM, Miller J, Meyer NM, Lenhart GM 
Truven Health Analytics, Cambridge, MA, USA  
OBJECTIVES: To describe the costs and clinical outcomes of global endometrial 
ablation (GEA) and hysterectomy for the treatment of menorrhagia among 
women insured through Medicaid programs. METHODS: The Truven Health 
MarketScan® Medicaid Multi-State Database was used to identify Medicaid 
recipients aged 30-55 years with diagnosed menorrhagia who initiated treatment 
for menorrhagia with GEA or hysterectomy during 2006-2010. Patients were 
required to have 12 months of continuous enrollment pre- and post-treatment 
initiation (index event). Baseline characteristics were assessed in the year prior 
to treatment initiation. Health care utilization and costs (2011 USD) were 
assessed in the year following treatment initiation. RESULTS: A total of 1880 
women met the study criteria (mean age=40.7); approximately one-half (53.4%) 
were Caucasian, 33.1% were African-American, and 2.3% were Hispanic. Nearly 
one-half (42.8%) of the women received their Medicaid eligibility due to 
disability. Slightly more patients received GEA (50.9%) than hysterectomy (49.1%). 
Both GEA and hysterectomy patients had similar baseline Deyo-Charlson 
Comorbidity scores (0.65) and similar baseline use of anti-biotics (69.4%), non-
steroidal anti-inflammatory drugs (56.3%), or oral contraceptives (5.3%). More 
than one-half (52%) of hysterectomy patients had a treatment-related 
complication, compared to 36% of GEA patients (p<0.0001). Index treatment costs 
plus 30-day follow-up costs were higher for hysterectomy ($11,270) than for GEA 
($3,958, p<0.0001). Gynecologic-related costs in the remainder of the year were 
$694 for hysterectomy and $175 for GEA (p=0.14). Nearly all GEA (93%) procedures 
occurred in an outpatient setting while 87% of hysterectomies occurred in an 
inpatient setting. CONCLUSIONS: Hysterectomy and related post-operative costs 
were nearly 3 times higher than GEA costs for the treatment of menorrhagia. 
These results and others from this study are timely, as new federal mandates for 
Medicaid expansion are likely to focus on outpatient treatments as ways to 
reduce Medicaid costs.  
